CSIMarket
 



Clarus Therapeutics Holdings Inc.  (CRXT)
Other Ticker:  
 
 



 

What are Clarus Therapeutics Holdings's Business Segments?



Clarus Therapeutics Holdings Inc. is a pharmaceutical company that specializes in developing and commercializing innovative therapies for various diseases and medical conditions. The company primarily focuses on segments related to men's health and reproductive medicine.

Segments:
1. Men's Health: Clarus Therapeutics caters to the specific health needs of men by offering products and services that target hormonal imbalances and related disorders. This segment includes treatment solutions for conditions such as hypogonadism, which is a deficiency in the production of testosterone.

Products:
1. Oral Testosterone Replacement Therapy: The flagship product of Clarus Therapeutics is JATENZO' (testosterone undecanoate), an oral testosterone replacement therapy for adult males diagnosed with hypogonadism. It is the first FDA-approved oral testosterone product in the United States.

Services:
1. Medical Support and Education: Clarus Therapeutics provides comprehensive medical support and education to healthcare professionals, patients, and caregivers. This includes information on the diagnosis and management of hypogonadism, treatment guidelines, and other related educational resources.

2. Patient Assistance Programs: The company offers patient assistance programs to provide affordable access to their medications. These programs may include financial assistance, co-pay support, or access to prescription savings cards, ensuring that patients can receive the necessary treatment without financial barriers.

3. Physician Resources: Clarus Therapeutics provides various resources for healthcare professionals, including clinical data, publications, and continuing medical education (CME) activities. These resources help physicians stay updated with the latest advancements in men's health and testosterone replacement therapy.

4. Research and Development: As a pharmaceutical company, Clarus Therapeutics continually invests in research and development to explore new therapeutic opportunities and advance their product pipeline. This includes conducting clinical trials to evaluate the safety and efficacy of potential treatments for conditions related to men's health.

Overall, Clarus Therapeutics Holdings Inc. focuses on delivering innovative therapies and comprehensive support services to address the specific healthcare needs of men, primarily in relation to hormonal imbalances and reproductive medicine.
   

Clarus Therapeutics Holdings Tax Rate Companies within the Biotechnology & Pharmaceuticals Industry


Business Segments Q2
Revenues
(in millions $)
Q2
Income
(in millions $)
(Jun 30 2022)
%
(Profit Margin)
Total 4.05 -10.69 -

Growth rates by Segment Q2
Y/Y Revenue
%
(Jun 30 2022)
Q/Q Revenue
%
Q2
Y/Y Income
%
(Jun 30 2022)
Q/Q Income
%
Total - 0.97 % - -

To get more information on Clarus Therapeutics Holdings's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com